In the JAVELIN Renal 101 trial, avelumab (Bavencio®, Merck and Pfizer) (anti-PD-L1) was combined with the VEGFR inhibitor, axitinib, and led to FDA approval in 2019 for patients with untreated advanced RCC. Here, CD274 is linked to renal cell carcinoma.